Acadia Pharmaceuticals
ACAD
308 hedge funds and large institutions have $7.91B invested in Acadia Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 75 funds opening new positions, 93 increasing their positions, 98 reducing their positions, and 31 closing their positions.
142% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 31
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
28% more capital invested
Capital invested by funds: $6.19B → $7.91B (+$1.72B)
24% more call options, than puts
Call options by funds: $55.4M | Put options by funds: $44.6M
15% more funds holding
Funds holding: 267 → 308 (+41)
5% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 98
1.43% less ownership
Funds ownership: 94.48% → 93.06% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$96.8M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$44.3M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$41.6M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$26.2M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$23.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$132M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$64.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$59.6M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$39.3M |
| 5 |
Janus Henderson Group
London,
|
-$30.9M |
ACAD Hedge Fund Activity: Q4 2020 in Review
308 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2020, worth a combined $7.91B — up 28% from $6.19B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new ACAD positions and 31 closed out — a net gain of 44 holders — while 93 added to existing stakes and 98 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $96.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $132M.
- 308 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2020, up from 267 in Q3 2020.
- Funds reported $7.91B of Acadia Pharmaceuticals stock for Q4 2020, up 28% quarter-over-quarter.
- 75 funds opened new Acadia Pharmaceuticals positions in Q4 2020 and 31 closed out, a net change of +44 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2020 was Avoro Capital Advisors, an estimated $96.8M added.
- The largest Acadia Pharmaceuticals seller in Q4 2020 was T. Rowe Price Associates, an estimated $132M sold.
Based on aggregated 13F filings for Q4 2020.